Phase 3 Clinical Trials – Page 3

Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval

9 months ago talkbio0Tagged Approved, Boehringer, FIBRONEER-ILD, fibrosing, Improvement, Ingelheim, Inhibitor, nerandomilast, PF-ILDs, Phase 3 Clinical Trials, phosphodiesterase 4B, Progressive, Respiratory physiology, United States Food and Drug Administration

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor

Tris Pharma Achieves Significant Milestone with Non-Opioid Painkiller Cebranopadol in Phase III Trials

9 months ago talkbio0Tagged abuse potential, Agonist, Cebranopadol, Dual-NMR, non-opioid pain medication, Pain management, Phase 3 Clinical Trials, Reduced, Tris Pharma

Non-opioid pain medication, Cebranopadol, Tris Pharma, Phase III trials, Pain management, Reduced abuse potential, Dual-NMR agonist

Boehringer Ingelheim’s Iclepertin Fails to Meet Primary and Secondary Endpoints in Phase III Schizophrenia Trials

9 months ago talkbio0Tagged Boehringer Ingelheim, CONNEX, Iclepertin, Impaired cognition, Phase 3 Clinical Trials, Programs - Publication Format, Schizophrenia

Boehringer Ingelheim, iclepertin, schizophrenia, Phase III trials, cognitive impairment, CONNEX program

High-Dose Wegovy Demonstrates Enhanced Weight Loss in Phase III Trial

9 months ago talkbio0Tagged Nordisk, Novo Nordisk, Obesity, Phase 3 Clinical Trials, semaglutide, Step (specific stage), Up, Wegovy

Wegovy, semaglutide, obesity treatment, weight loss, Novo Nordisk, Phase III trial, STEP UP trial

Sotyktu Expands Potential with Successful Phase III Trials in Psoriatic Arthritis

10 months ago talkbio0Tagged Arthritis, Psoriatic, deucravacitinib, Inhibitor, Myers, Phase 3 Clinical Trials, Sotyktu, squibb, TYK2 gene

Sotyktu, deucravacitinib, psoriatic arthritis, Phase III trials, Bristol Myers Squibb, TYK2 inhibitor

Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion

10 months ago talkbio0Tagged Bayer, Biosimilars, competition, expansion, Eylea HD, Macular retinal edema, Phase 3 Clinical Trials, Regeneron, Retinal Vein Occlusion

Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition

Candel Therapeutics Sees Dramatic Stock Surge Following Successful Phase III Prostate Cancer Trial

11 months ago talkbio0Tagged Approved, CAN-2409, Candel, Malignant neoplasm of prostate, Phase 3 Clinical Trials, surge, United States Food and Drug Administration, viral immunotherapy

Candel Therapeutics, CAN-2409, Phase III trial, prostate cancer, viral immunotherapy, stock surge, FDA approval

Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials

11 months ago talkbio0Tagged Antonio Breast Cancer Symposium, ER-positive, HER2-negative, Malignant neoplasm of breast, NAA50 gene, Olema Oncology, Oral SERD, palazestrant, Phase 3 Clinical Trials, SABCS

Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)

Agios’ Thalassemia Drug Mitapivat Faces Liver Injury Concerns Despite Second Phase III Success

11 months ago talkbio0Tagged Agios, ENERGIZE-T, Injury of liver, Mitapivat, Phase 3 Clinical Trials, regulatory approval, Thalassemia

Agios Pharmaceuticals, Mitapivat, Thalassemia, Liver Injury, Phase III Trials, ENERGIZE-T Study, Regulatory Approval

FDA Approves Imfinzi for Limited-Stage Small Cell Lung Cancer, Marking First Systemic Immunotherapy for LS-SCLC

11 months ago talkbio0Tagged ADRIATIC, Approved, Breakthrough Therapy, durvalumab, Identifier, Imfinzi, Limited-stage, LS-SCLC, Phase 3 Clinical Trials, Priority Review, Systemic Immunotherapy, United States Food and Drug Administration

Imfinzi (durvalumab), Limited-stage small cell lung cancer (LS-SCLC), FDA approval, Systemic immunotherapy, ADRIATIC Phase III trial, Breakthrough Therapy Designation, Priority Review